We have begun collecting samples for the expanded antibody list, which will include 426 antibodies that now include additional DNA repair and immune-oncology pathways. For now, we will only be offering the expanded antibody panel, but may decide to offer the choice between two panels: 1. our expanded panel of 426 antibodies or 2. the previous panel of 304 antibodies based on feedback received in the future. The pricing now reflects the increased charge that compensates for the costs of additional materials associated with the antibody expansion. The expanded antibody list can be viewed on the Antibody Information and Protocols page.
Please contact Kathryn Aziz at email@example.com if you have questions or concerns. We look forward to being able to make these additional antibodies available to you to help further your research!
The Reverse Phase Protein Array (RPPA) Core provides investigators with a powerful, high‐throughput, quantitative, cost‐effective technology for functional proteomics studies. Furthermore, we provide centralized, standardized and quality-controlled services to investigators not only throughout MD Anderson, but around the world, as well as to several national consortia, including TCGA, CCLE and ICBP.
RPPA represents an antibody‐based functional proteomic analysis for both tumor tissue and cultured cells. RPPA characterizes the basal protein expression and modification levels, growth factor‐ or ligand‐induced effects, and time‐resolved responses appropriate for systems biology analysis. It provides information to integrate the consequence of genetic aberrations in cancer, to validate therapeutic targets, to demonstrate on‐ and off‐target activity of drugs, and to evaluate drug pharmacodynamics.
Advantages of Functional Proteomics & RPPA
Studies of complex diseases such as cancer have shown that genetic alterations do not account for all of the causes of the disease. Changes in protein levels and structure have also been shown to play critical roles in tumor development and progression, which are not reflected by genetic changes. In cancers, several genetic and epigenetic changes are often required for development of the disease. Studying large-scale epigenetic changes such as protein phosphorylation or cleavage will greatly aid in understanding the causes and determining effective treatment of cancers and other complex diseases.
The core has defined a set of standard lysates to be used in each array for quality control (QC) of data generation and analysis. A set of algorithm and custom software applications has been developed to improve quantification and quality control.
- Cost effective: A high throughput approach concurrently tests and quantifies over 1000 samples on a signal slide.
- Sensitive: Applicable to very small sample sizes (ng of protein lysates, detecting attomoles of aspecific protein), less than 10 cell equivalents. It detects and quantifies hundreds of different proteins at expression levels and modification status in 40 ug of cell lysates.
- Quantitative: Recombinant protein/phosphopeptides enable absolute quantification of protein expression and modification levels.
- Simple: Does not require direct labeling of the lysate sample.
Core Grant Citation
This facility is funded by NCI # CA16672. Publications should cite the Core grant in the acknowledgment section, if publications use data generated by the RPPA Core facility. Two copies of the publication acknowledging the Core grant should also be submitted to the facility at Unit 1058.